SCHEMBL9985285

SCHEMBL9985285

CCCCNc1ccc([N+](=O)[O-])c(Nc2ccc(-c3csc(C4CCCCC4)n3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
POLB P06746 2/20 0.35
MEN1 O00255 1/20 0.35
NFKB1 P19838 1/20 0.35
MAPK1 P28482 1/20 0.35
NFKB2 Q00653 1/20 0.35
KMT2A Q03164 1/20 0.35
RELA Q04206 1/20 0.35
BRD4 O60885 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
RIPK1 Q13546 1/20 0.33
HSF1 Q00613 1/20 0.33
CTSL P07711 1/20 0.33
CTSB P07858 1/20 0.33
CTSS P25774 1/20 0.33
MAOB P27338 6/20 0.33
MAOA P21397 4/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9984114 0.88 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1NPC1RAB9ABRD4
SCHEMBL9984326 0.87 HSF1 (0.45) SMN1; SMN2ALDH1A1NPC1RAB9APOLB
SCHEMBL9984498 0.86 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9AMEN1
SCHEMBL9984250 0.85 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1NPC1RAB9APOLB
SCHEMBL9984823 0.85 BRD4 (0.49) SMN1; SMN2ALDH1A1NPC1RAB9ABRD4
SCHEMBL9983861 0.84 ALDH1A1 (0.40) SMN1; SMN2ALDH1A1NPC1RAB9APOLB
SCHEMBL9983846 0.84 DRD2 (0.38) SMN1; SMN2ALDH1A1NPC1RAB9AMEN1
SCHEMBL9984494 0.83 BRD4 (0.39) SMN1; SMN2ALDH1A1NPC1RAB9APOLB
SCHEMBL9984465 0.82 ADRB1 (0.40) SMN1; SMN2ALDH1A1NPC1POLBMEN1
SCHEMBL9984262 0.81 SMN1; SMN2 (0.43) SMN1; SMN2ALDH1A1NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US claimed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP claimed
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME DONG WHA PHARM. CO., LTD. (KR) 2011-12-15 US disclosed
EP-2394993-A2 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME Dong Wha Pharm. Co., Ltd. (KR) 2011-12-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306606-A1 NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME NOS3, PTMS, NOS2 SMN1; SMN2 2176/4885ALDH1A1 2401/4885NPC1 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.